Chaudhary L R, Avioli L V
Department of Internal Medicine, Washington University School of Medicine at Barnes-Jewish Hospital, St. Louis, MO 63110, USA.
Mol Cell Biochem. 1998 Jan;178(1-2):59-68. doi: 10.1023/a:1006807221545.
The mitogen-activated protein (MAP) kinases (p44mapk and p42mapk), also known as extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2), are activated in response to a variety of extracellular signals, including growth factors, hormones and, neurotransmitters. We have investigated MAP kinase signal transduction pathways in normal human osteoblastic cells. Normal human bone marrow stromal (HBMS), osteoblastic (HOB), and human (TE85, MG-63, SaOS-2), rat (ROS 17/2.8, UMR-106) and mouse (MC3T3-E1) osteoblastic cell lines contained immunodetectable p44mapk/ERK1 and p42mapk/ERK2. MAP kinase activity was measured by 'in-gel' assay using myelin basic protein as the substrate. Mainly ERK2 was rapidly activated (within 10 min) by bFGF, IGF-I and PDGF-BB in normal HOB, HBMS and human osteosarcoma cells, whereas both ERK1 and ERK2 were activated by growth factors in rat osteoblast-like cell lines, ROS 17/2.8 and UMR-106. The ERK1 activation was greater than the ERK2 in ROS 17/2.8 cells. Furthermore, ERK2 was also activated by bFGF and PDGF-BB in the mouse osteoblastic cell line, MC3T3-E1. This is the first demonstration of inter-species differences in the activation of MAP kinases in osteoblastic cells. Cyclic AMP derivatives or cAMP generating agents such as PTH and forskolin inhibited ERK2 activation by bFGF and PDGF-BB suggesting a 'cross-talk' between the two different signalling pathways activated by receptor tyrosine kinases and cAMP-dependent protein kinase. The accumulated results also suggest that the MAP kinases may be involved in mediating mitogenic and other biological actions of bFGF, IGF-I and PDGF-BB in normal human osteoblastic and bone marrow stromal cells.
丝裂原活化蛋白(MAP)激酶(p44mapk和p42mapk),也被称为细胞外信号调节激酶1和2(ERK1和ERK2),可响应多种细胞外信号而被激活,这些信号包括生长因子、激素和神经递质。我们已经研究了正常人成骨细胞中的MAP激酶信号转导途径。正常人骨髓基质(HBMS)、成骨(HOB)以及人(TE85、MG-63、SaOS-2)、大鼠(ROS 17/2.8、UMR-106)和小鼠(MC3T3-E1)成骨细胞系中含有可通过免疫检测到的p44mapk/ERK1和p42mapk/ERK2。使用髓鞘碱性蛋白作为底物,通过“凝胶内”试验测定MAP激酶活性。在正常HOB、HBMS和人骨肉瘤细胞中,主要是ERK2被碱性成纤维细胞生长因子(bFGF)、胰岛素样生长因子-I(IGF-I)和血小板衍生生长因子-BB(PDGF-BB)迅速激活(在10分钟内),而在大鼠成骨样细胞系ROS 17/2.8和UMR-106中,ERK1和ERK2均被生长因子激活。在ROS 17/2.8细胞中,ERK1的激活程度大于ERK2。此外,在小鼠成骨细胞系MC3T3-E1中,ERK2也被bFGF和PDGF-BB激活。这是首次证明成骨细胞中MAP激酶激活存在种间差异。环磷酸腺苷(cAMP)衍生物或产生cAMP的试剂,如甲状旁腺激素(PTH)和福斯可林,可抑制bFGF和PDGF-BB对ERK2的激活,这表明受体酪氨酸激酶和cAMP依赖性蛋白激酶激活的两种不同信号通路之间存在“串扰”。累积的结果还表明,MAP激酶可能参与介导bFGF、IGF-I和PDGF-BB在正常人成骨细胞和骨髓基质细胞中的促有丝分裂及其他生物学作用。